ERBB2 and breast carcinoma: By providing new paths for precision medicine in the treatment of luminal, HER2+, and TNBC subtypes, an understanding of the molecular processes involving STIL and SAS6 in breast cancer subtypes holds promise for the development of novel targeted therapeutics.